In retrospect, it is tempting to wonder if this patient’s GCA and the complications of both GCA and its treatments might have been avoided if the patient had initially accepted treatment of her PMR with low-dose steroids. It would be unfortunate if her fear of medications actually resulted in the need to use even more medications. However, this is purely speculative, because we could find no data to support the theory that treating PMR early in its course might prevent the later development of GCA. Perhaps this could be an area of future study in the form of a retrospective case series, because a prospective study randomizing patients to delay treatment of PMR would be unethical.
You Might Also Like
Explore This IssueNovember 2018
Erin Hammett, DO, is a rheumatology fellow at Scripps Clinic/Scripps Green Hospital La Jolla, Calif. She completed her internal medicine residency at Santa Barbara Cottage Hospital.
Edward Skol, MD, is a rheumatology attending at Scripps Clinic/Scripps Green Hospital La Jolla, Calif. He completed his internal medicine residency at Scripps Mercy Hospital and rheumatology fellowship at Scripps Clinic/Scripps Green Hospital.
- Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008 Jul 19;372(9634):234–245.
- Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics. 1989 spring;30(2):135–139.
- Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017 Jul 27;377(4):317–328.
- Tomasson G, Peloquin C, Mohammad A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: A cohort study. Ann Intern Med. 2014 Jan 21;160(2):73–80.
- Schmidt WA, Natusch A, Möller DE, et al. Involvement of peripheral arteries in giant cell arteritis: A color Doppler sonography study. Clin Exp Rheumatol. 2002 May–Jun;20(3):309–318.
- Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum. 2006 Feb;55(1):131–137.
- Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017 Apr;69(4):837–845.